Abstract |
A pilot study was performed to evaluate the feasibility and efficacy of irinotecan hydrochloride (CPT-11) plus carboplatin ( CBDCA) for treatment of advanced or recurrent colorectal cancer. Fifteen patients with colorectal cancer (nonresectable, 1; noncurative resection, 5; recurrent disease, 9) were treated with CPT-11 (40-50 mg/m2) plus CBDCA (70-100 mg/m2) once a week for 2-3 weeks followed by a one-week rest. This treatment was repeated until disease progression or severe toxic effects were found. The total dose of CPT-11 ranged from 135 to 1,214 (median, 467) mg/m2 and that of CBDCA ranged from 267 to 2,022 (median, 933) mg/m2. Adverse effects included nausea (grade 2) in 2 (13.3%) diarrhea (grade 2) in 2 (13.3%), leukopenia (grade 3) in 2 (13.3%), thrombocytopenia (grade 1) in one (6.7%), and hair falling (grade 3) in one (6.7%). The response rate of 14 evaluable patients was 14.3% (CR, 1; PR,1; NC,7; PD,5). The median survival time of all patients was 405 days from the start of chemotherapy. The survival time of patients with CR, PR, and NC (n = 9) tended to be longer than that of those with PD (n = 5) (p = 0.06). The median time to disease progression was 105 days. These results suggest that this combination chemotherapy is feasible and effective in the treatment of advanced or recurrent colorectal cancer.
|
Authors | H Ishida, I Takeuchi, T Ohsawa, H Nakada, N Ishizuka, M Yokoyama, H Okita, S Inokuma, T Suzuki, H Yamada, A Odaka, T Takahama, N Murata, M Fujioka, D Hashimoto, Y Idezuki |
Journal | Gan to kagaku ryoho. Cancer & chemotherapy
(Gan To Kagaku Ryoho)
Vol. 27
Issue 9
Pg. 1411-4
(Aug 2000)
ISSN: 0385-0684 [Print] Japan |
PMID | 10969597
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Irinotecan
- Carboplatin
- Camptothecin
|
Topics |
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Camptothecin
(administration & dosage, analogs & derivatives)
- Carboplatin
(administration & dosage)
- Colorectal Neoplasms
(drug therapy, pathology)
- Drug Administration Schedule
- Feasibility Studies
- Female
- Humans
- Irinotecan
- Male
- Middle Aged
- Neoplasm Recurrence, Local
(drug therapy)
- Pilot Projects
- Survival Analysis
|